Yinjia Bio Showcases AI-Driven Protein Innovation at 'Biomanufacturing' Institutional Day, Attracting Investor Attention Ahead of IPO Filing

In early April 2026, against the backdrop of the "15th Five-Year Plan" designating biomanufacturing as a core sector for future industries, the Yuhuang Mountain South Fund Town in Hangzhou, Gaorong Venture Capital, and the international venture capital ecosystem service platform Entrepreneur jointly initiated the "Biomanufacturing" Institutional Day Summit. The event invited leading enterprises in the relevant industries and friends from the investment community to gather at the beautiful Yuhuang Mountain South Fund Town in Hangzhou to discuss "Industrialization Pathways and Commercial Application Breakthroughs in Biomanufacturing."YINJIA BIOSCIENCES, as a representative of an AI-driven high-end protein innovation platform enterprise, was invited to attend. The company's founder and CEO, Dr. Wu Yifei, gave a presentation."Technical Challenges and Commercialization Based on First Principles"The keynote speech systematically elaborated on how to fundamentally address the efficiency and cost bottlenecks in biomanufacturing based on the "Five-Step Method" theory derived from first principles, achieving accelerated R&D closed-loop and commercial breakthroughs, and discussed and exchanged ideas with industry peers.

In the keynote speech, Dr. Wu Yifei also introducedYINJIA BIOSCIENCES, guided by the first principles, has built a coverage fromFrom metabolic bottleneck analysis, AI-assisted protein design, cell-free rapid prototyping validation, to process scaling and commercial adaptation of the entire chainThe "Five-step Method" systematic application framework achieves an efficient closed-loop iteration of AI predictive capabilities and wet-lab validation.Under the guidance of this application framework, the company has developedA microscale cell-free protein expression system suitable for high-throughput screening can achieve efficient expression of multiple proteins in a reaction system of <10ul.With this brand-new cell-free protein expression system inNovel Turing Protein ChipExperimentally validated above, canSignificantly shorten the closed-loop cycle of "AI protein design-high-throughput experimental validation-redesign".To elevate the efficiency of novel protein development to new heights.

Gaorong Venture Capital is one of the early lead investors in YINJIA BIOSCIENCES and also one of the organizers of this event. At the conference, Dr. Bei Lin, Managing Director of Gaorong Venture Capital, shared his analysis of the development prospects of the biomanufacturing industry and his investment philosophy. He also pointed out that with the continuous innovation of AI technology platforms, the connection between AI technology and the biomanufacturing industry is becoming increasingly close.YINJIA BIOSCIENCES' thematic presentation at this conference fully demonstrated the company's core technical advantages and the "powerful combination" achieved through the AI platform, showcasing the benchmark value of AI+ in empowering the biomanufacturing sector.

In the subsequent roundtable discussion, representatives from innovative companies such as Huifeng Gene, Shiqi Biochemistry, Evolution Silicon, and Kairui Bio also shared cutting-edge insights from perspectives like technological positioning and commercialization choices, jointly outlining a diversified development landscape for the biomanufacturing industry.

As the "15th Five-Year Plan" identifies biomanufacturing as a new economic growth point, the deep integration of AI and biomanufacturing is evolving from an "auxiliary tool" to a "core driving force."YINJIA BIOSCIENCES will continue to leverage the industry resources of top investment institutions, including Gaorong Capital, to accelerate the flywheel effect of AI design-protein manufacturing-commercial application, and is committed to becoming a leader in AI-driven innovative proteins.

YINJIA BIOSCIENCES is an AI-driven developer and producer of high-end proteins and quality control and safety evaluation testing reagents for therapeutic biologics. It has secured three rounds of financing worth hundreds of millions of yuan led by top investment institutions such as CDH Investments, Gaorong Capital, and CMB International. The company has established an enabling AI-protein design and prediction platform, a high-throughput cell-free protein expression platform, a comprehensive protein platform centered on unique protein design and complex process development, a quality control and safety evaluation development platform for therapeutic biologics, and a synthetic biotechnology platform based on gene editing and microbial chassis cell modification. Its products cover cutting-edge fields such as ADC/antibody new drug research and development, vaccines, cell therapy, proteomics, organoids/stem cells, and have provided high-quality, stable products comparable to imported ones for leading listed pharmaceutical companies, innovative drug companies, diagnostic companies, and academic research institutes in China.